Title:Chemotherapeutics for Acute Erythroid Leukemia: Research, Present and Future
Volume: 21
Issue: 10
Author(s): Zexi Liao, Jiaxin Li, Jingjing Wu, Jing Liu*Shuming Sun*
Affiliation:
- Molecular Biology Research Center, School of Life Sciences, Central South University, Changsha, 410078,China
- Molecular Biology Research Center, School of Life Sciences, Central South University, Changsha, 410078,China
Keywords:
Acute erythroid leukemia, acute myeloid leukemia, chemotherapeutic agents, erythroid differentiation,
GATA-1, GATA-2, Gfi1b, EKLF, EPO-related pathways.
Abstract: Acute erythroid leukemia (AEL) is a subtype of acute myeloid leukemia (AML)
with features such as accumulation of maturation-arrested erythroblasts. Compared with
AML, the progression of AEL is faster and the prognosis to available therapy is worse.
However, its categorization is still being updated and the pathophysiology of AEL is still
under research, making diagnosis and chemotherapy challenging for physicians. To
achieve better outcomes, therapies should be optimized and new drugs should be
developed. In this review, we summarize current strategies of diagnosis and therapies of
AEL, and discuss prospective targets for chemotherapeutic agents based on the
biological characteristics of AEL neoplastic cells as well as transcriptional factors and
pathways related to erythroid differentiation.
